Dr Connolly highlights the cautious patient selection and the significance of reducing hematoma expansion for improved outcomes in cases of intracerebral hemorrhage (ICH) associated with the use of a reversal agent for factor Xa inhibitors.
A medical expert discusses the findings of a randomized trial investigating the use of andexanet alfa versus usual care in patients with acute intracerebral hemorrhage (ICH) and recent direct oral anticoagulant (DOAC) use.
The phase 4 ANNEXA-I trial was stopped early after showing superior hemostatic efficacy and the capability to limit potentially life-threatening intracerebral hemorrhage (ICH) compared with usual care in patients taking oral factor Xa (FXa) inhibitors.
AstraZeneca to proceed with regulatory filings to convert from conditional to full approval in the US and EU
ANNEXA-I, a post-marketing Phase IV trial to assess the efficacy and safety of Andexxa in. | June 5, 2023